Abstract: Erythropoietin is a potent stimulator of erythroid progenitor cells, which is able to inhibit NF-kB activation, due to its pleiotropic properties, thus promoting an anti-inflammatory effect. As inflammatory bowel disease is a chronic disease with reduced quality of life, and the current pharmacotherapy only induces or maintains the patient in remission, there is a crucial need of new pharmacological approaches. The main objective of this study was to evaluate the effect of erythropoietin in the TNBS-induced colitis model in mice with a normal intestinal flora. Mice with TNBS-induced colitis were treated with a daily dose of erythropoietin at 500 IU/kg bw/day and 1000 IU/Kg bw/day IP during 4 days. As to clinical symptoms/signs, erythropoietin attenuated the decreased body-weight and reduced diarrhoea and oedema of the anus registered in the non-treated mice group in a dose-dependent manner. The anti-inflammatory properties of erythropoietin in the TNBS-induced colitis were confirmed by suppression of pro-inflammatory mediators, such as TNF-a, IL-1b and MPO, as well as a significant increase in the anti-inflammatory cytokine, IL-10, was promoted. These treated mice also presented a reduction in haemoglobin faecal and ALP, suggesting a beneficial effect of erythropoietin in the haemorrhagic focus and destruction of the enterocyte associated with the colon injury induced by TNBS, respectively. The histopathological score was reduced after treatment with erythropoietin, decreasing the severity and extension of the colitis. Furthermore, renal and hepatic biomarkers, as well as haematocrit concentration, remained stabilized after treatment. In conclusion, erythropoietin reduces the inflammatory response associated with TNBSinduced colitis in mice.
Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract, characterized by chronic recurrent ulceration of the bowels [1] . IBD affects 7-10% of people worldwide, mainly of Caucasian descent [2, 3] , promoting significant gastrointestinal symptoms, like bloody diarrhoea, abdominal pain, rectal urgency, tenesmus and other extra-intestinal manifestations [1] .
Currently used medical therapy of IBD consists of salicylates, corticosteroids, monoclonal antibodies and immunosuppressants [1] . These drug treatments aim to induce or maintain the patient in remission, rather than modifying or reversing the underlying pathogenic mechanism [1, 4] . Their use may result in severe side effects and complications, such as increased rate of malignancies or infectious diseases [1] . Research into new pharmacological approaches is crucial to the treatment of IBD.
Erythropoietin (EPO) is a multifunctional glycoprotein essential for the haematopoietic system, regulating the bone marrow erythrocyte production by differentiation and inhibition of the apoptosis of erythroid progenitor cells [5] . Moreover, EPO also has non-haematopoietic properties, through EPO receptors' interaction that are expressed on various nonerythroid tissues, such as the brain, retina, heart, skeletal muscle, kidney and endothelial cells [6] [7] [8] . The nonhaematopoietic activities of EPO may be due to the presence of heterodimeric receptors composed of EPOR subunit disulphide linked with beta common receptors (EPOR-bcR). Therefore, EPO promotes a blockage of nuclear factor (NF)-kB p65 activation and inactivation of GSK-3b, via activation of PI3K-Akt, as well as inactivation of cyclooxygenase 2 (COX-2), caspases 3-8 and stimulation of IL-10 production [5, 9, 10] . Through these multiple mechanisms of action, EPO presents an important role in the reduction in inflammation, apoptosis, and oxidative stress, due to hypoxia, toxicity, or injury [5, 11, 12] .
Erythropoietin can be a possible new strategy of IBD, and some studies have been developed to evaluate its efficacy [10, [13] [14] [15] . The typical intestinal injuries of IBD reveal different characteristics and location, in the Crohn's disease and ulcerative colitis [16] thus, it is crucial to evaluate the efficacy of EPO treatment in the context of each of these pathologies. The TNBS-induced colitis mimics the pattern of inflammation with human IBD [17, 18] , promoting a transmural colonic injury characteristic of Crohn's disease [19] . To our knowledge, there is only one published study that evaluated the influence of EPO treatment in TNBS-induced colitis, but these mice presented an intestinal infection framework [10] . As it is generally agreed that an infectious environment is an additional variable that contributes to disease initiation and its progression [20] [21] [22] , future studies are needed to clarify the anti-inflammatory property of EPO under a normal intestinal bacterial flora [13] . Furthermore, EPO doses used in this study Author for correspondence: Rui Manuel Amaro Pinto, Department of Pharmacological Sciences, Faculty of Pharmacy -University of Lisbon, 1649-003 Lisbon, Portugal (fax (+351) 217946470, e-mail rapinto@ff.ulisboa.pt).
were lower than those used in other studies, facilitating the translation of the obtained results to clinical practice. Thus, the main objective of this study was to evaluate the effect of EPO in the inflammatory response associated with TNBSinduced colitis model in mice with a normal intestinal flora.
Materials and Methods
Drugs and chemicals. 2,4,6-Trinitrobenzene sulphonic acid (TNBS 5%) was purchased from Sigma-Aldrich Chemical (Sintra, Portugal). Erythropoietin (Eprex â 10000 IU/ml) was purchased from Janssen- Induction of experimental colitis. Erythropoietic effects are expressed at 10 days after EPO treatment [23] . As this study intended to evaluate the non-erythropoietic effects of EPO, which may be relevant in the acute intestinal crisis of IBD, an acute model of experimental colitis was induced with TNBS and used to evaluate the EPO effect. TNBS was instilled an intracolonic single dose as previously described by Morris and colleagues [19] . Briefly, mice were left unfed during 24 hr. On the induction day (day 0), the mice were anaesthetized with ketamine 100 mg/Kg + xylazine 10 mg/Kg. Then, 100 ll of TNBS solution was administered through a catheter carefully inserted until 4 cm into the colon. The mice were kept for 1 min. in a Trendelenburg position to avoid reflux. Four days after induction, they were anaesthetized and blood samples were collected by cardiac puncture. The mice were killed by cervical dislocation and necropsied. The abdomen was opened by a midline incision. Colon was removed, freed from surrounding tissues and washed with phosphate-buffered saline. Colon length was also measured.
Experimental groups. Experimental groups were categorized as follows: TNBS group (n = 35) received 100 ll intrarectal 2.5% TNBS in 50% ethanol; TNBS+EPO500 group (n = 35) and TNBS+EPO1000 group (n = 35) were a TNBS-induced colitis model treated daily with 500 IU/kg bw/day and 1000 IU/kg bw/day IP of EPO (dissolved in saline solution) from the induction day, respectively; EPO1000 group (n = 20) only received 1000 IU/kg bw/day IP of EPO daily from the induction day (to evaluate the safety associated with EPO treatment); ethanol group (n = 20) received 100 ll intrarectal 50% ethanol (TNBS vehicle); and sham group (n = 20) received a 100-ll intrarectal saline solution. Thus, the ethanol group was used as a reference to compare the results with the other experimental groups. After induction, the animals were observed daily, monitoring bodyweight, stool consistency and anus appearance.
Biochemical markers. Serum from collected blood samples was separated by centrifugation at 3,600 rpm for 15 min. and analysed by an automated clinical chemistry analyser (ADVIA â 1200). Biochemical markers were evaluated, such as alkaline phosphatase (ALP), urea, creatinine, alanine aminotransferase (ALT) and haematocrit. Faecal haemoglobin was evaluated using a quantitative method by immunoturbidimetry (Kroma Systems).
Myeloperoxidase concentration. Neutrophil infiltration to the inflamed colon was indirectly quantitated using an MPO assay and expressed in ng/ml. The colon was weighed, homogenized (Ultra-turrax T25, 13,500 rev/min., twice for 30sec.) in phosphate buffer and then centrifuged (at 15,000 rpm for 15 min. at 4°C). The aliquots of the supernatant were stored at À20°C until use. An aliquot of the supernatant was incubated in microtiter wells coated with biotinylated tracer antibody, recognizing mouse MPO. Streptavidin-peroxidase conjugate was added to bind the biotinylated tracer antibody and then mixed with tetramethylbenzidine substrate. The reaction was stopped by the addition of oxalic acid and assayed spectrophotometrically at 450 nm (ELISA kit HK210, Hycult Biotech).
Measurement of cytokines. The TNF-a and IL-1b (pro-inflammatory cytokines) and IL-10 (anti-inflammatory cytokine) were measured and expressed as pg/ml. The colonic tissue samples were weighed and homogenized (Ultra-turrax T25, 13,500 rev/min., twice for 30 sec.) in phosphate buffer and then centrifuged (at 15,000 rpm for 15 min. at 4°C). The aliquots of the supernatant were stored at À20°C until use. The cytokine levels were measured spectrophotometrically at 450 nm (ELISA kit Quantikine, Hycult Biotechnology).
Microscopic assessment of colitis severity. Two independent histopathologists from the Faculty of Veterinary Medicine (FMV-ULHT) and Institute of Molecular Medicine (IMM) who were blinded to the treatment groups carried out the histopathological analysis. The intestine samples were fixed in 10% phosphate-buffered formalin, processed routinely for paraffin embedding, sectioned at 5 lm and stained with haematoxylin and eosin. Longitudinal sections of distal colon were evaluated based on adapted criteria of Corazza (1999) and Seamons (2013) and colleagues [24, 25] . The histopathological score of lesions were partially scored (0-4 increasing severity) with some parameters, namely: (1) presence of tissue loss/necrosis, (2) severity of mucosal epithelial lesion, (3) inflammation, (4) extent 1 -the percentage of intestine affected in any manner and (5) extent 2 -the percentage of intestine affected by the most severe lesion. The colitis severity was calculated by summing the individual lesions and the extent scores, promoting a final colitis score (max score=20).
Statistical analysis. All results were expressed as mean AE SEM of N observations, where n represents the number of animals studied. Data analysis was performed using GraphPad Prism 5.0 software (GraphPad, San Diego, CA, USA). The results were analysed by oneway ANOVA to determine statistical significance between the experimental and control groups followed by Tukey's post hoc test for multiple comparisons or chi-square test depending on the variables under study. A p-value of less than 0.05 was considered significant.
Results

Monitoring of clinical symptoms/signs.
Mice with TNBS-induced colitis presented a progressive fall in body-weight over the 4-day experimental period (À12.0 AE 1.4%), accompanied by diarrhoea and severe oedema of the anus. In the EPO-treated mice, the fall in bodyweight was attenuated, as well as the clinical signs of soft stools and moderate oedema of the anus. Particularly, daily treatment with EPO (500 IU/Kg bw/day) promoted only a loss of À3.7 AE 3.0% of initial weight. During treatment with 1000 IU/Kg bw/day of EPO, colitic mice inclusively gained 7.3 AE 3.8% (p < 0.0001, compared with TNBS group) of their initial weight. EPO1000, ethanol and sham groups remained without any alterations with respect to stool consistency and anus appearance during the study. At the end of the experimental period, they also gained 21.0 AE 2.7%, 15.2 AE 1.1% and 31.2 AE 1.6% (p < 0.0001, compared with the TNBS group) of its initial weight, respectively ( fig. 1) .
Biochemical markers.
The TNBS group presented a reduced colon length, increased faecal haemoglobin and ALP concentrations; however, EPO treatment was able to attenuate some of these parameters (table 1) . After EPO treatment, there was a tendency to increase the colon length in EPO-treated mice, but without statistically significant differences in the TNBS group. Colitic mice had their colon filled with severe bloody stools compared with the ethanol group, and EPO-treated mice presented a decrease in the intensity of haemorrhagic focus as a significant difference in faecal haemoglobin was also observed (p < 0.0001). Furthermore, ALP concentration also decreased on blood in the EPO-treated mice at both EPO doses (p < 0.0001). Curiously, ALP concentration in the EPO1000 group was significantly increased comparing with TNBS+EPO1000 (p < 0.01) and sham groups (p < 0.0001).
Extra-intestinal manifestations promoted by TNBS-induced colitis or by EPO treatment were evaluated through determination of urea and creatinine (renal function), ALT (hepatic function) and haematocrit (table 1). After intracolonic administration of TNBS, mice exhibited a significant increase in urea (p < 0.0001), creatinine (p < 0.0001) and ALT (p < 0.001) concentrations compared with the ethanol group. These clinical conditions in the renal and hepatic functions were attenuated when mice were treated with a daily dose of EPO during 4 days. Urea, creatinine and ALT levels presented values quite similar with the ethanol group (no statistical significance). Creatinine concentration was significantly higher after isolated EPO administration (EPO1000 group), and ALT levels were elevated after a single intracolonic administration of ethanol (ethanol group) comparing with the sham group (p < 0.0001). Regarding haematocrit level, this was not affected by administration of EPO, as similar values of haematocrit were detected between EPO-treated mice and non-colitic mice.
Myeloperoxidase concentration.
Myeloperoxidase concentration was measured in all experimental groups as a marker of neutrophil influx ( fig. 2) . TNBS-induced colitis promoted an increased MPO concentration comparing with the ethanol group (p < 0.0001). However, EPO-treated mice presented a decrease in MPO concentration at both EPO doses (p < 0.0001).
Measurement of cytokines.
After induction of experimental colitis by TNBS, cytokines become dysregulated in pathological conditions promoting a pro-inflammatory effect, such as TNF-a and IL-1b ( fig. 3) . Mice with TNBS-induced colitis revealed a significant increase in TNF-a and IL-1b compared with the ethanol group (p < 0.0001). However, EPO-treated mice exhibited a significant decrease in these pro-inflammatory cytokines (p < 0.0001 compared with the TNBS group), in a dose-dependent manner in the IL-1b concentration (p < 0.05). EPO1000 and ethanol groups presented values of TNF-a and IL-1b quite similar with the sham group, without statistically significant differences.
IL-10 measurements, as an anti-inflammatory cytokine, confirm the obtained results with TNF-a and IL-1b measurements, because usually the IL-10 decreases when the TNF-a and IL-1b increase under inflammatory conditions (fig. 4) . Therefore, EPO-treated mice showed a significant increase in IL-10 at the higher EPO dose (p < 0.0001), compared with the TNBS group. The EPO1000, ethanol and sham groups showed similar results.
Assessment of colitis severity.
Representative images translating the histopathological score for the experimental groups analysed are shown in fig. 5 . Briefly, the TNBS group displayed diffuse transmural necrosis with severe haemorrhaging, involving the mucosa, submucosa, muscle layer and serosa, and often associated with peritonitis. In the EPO-treated mice, similar lesions were seen, namely transmural necrosis but to a lesser extent and with a multifocal pattern, interspersed with areas in which the mucosal integrity was maintained. In these areas, there was mild-to-moderate epithelial erosion and ulceration, and severe inflammatory cell infiltration, extending to the submucosa. Ethanol group showed only mild epithelial erosion, and no lesions were observed in the EPO and sham groups.
Microscopic assessment allocated the experimental groups in a histopathological score, ranging between 0 and 20 ( fig. 6 ). Colitic mice had a final score substantially higher than the ethanol group (p < 0.0001). In the EPO-treated mice groups, the histopathological score decreased (p < 0.05). No statistically significant differences were found between EPO doses. More precisely, the interpretation of partial scores suggests that EPO treatment resulted in a decrease in the severity of colitis in each parameter under evaluation, but especially in the decrease in the mucosal loss (data not shown). This treatment also allowed a decrease in extension of colitis, especially with a decrease in the percentage of intestine affected by the most severe lesion. At the higher EPO dose, there was additionally identified a slight decrease in inflammation partial score and the percentage of intestine affected in any manner. EPO1000 and sham groups revealed a residual histopathological score; however, the ethanol group was the only control group with a histopathological score slightly higher, but without statistically significant differences compared with the sham group. These results are consistent with the histopathological images.
Discussion EPO, the principal hormone promoting the survival and differentiation of erythroid progenitor cells, is currently being used in the therapy of patients with chronic renal failure suffering from anaemia [10, 26] . However, there is scientific evidence that EPO also bears extra-haematopoietic properties, such as inhibition of the NF-jB pathway, decreasing the production of NF-jB-inducible immune mediators and, subsequently, limiting tissue damage and ameliorating disease severity [10] . Some studies have evaluated the influence of EPO on the experimental colitis, but much more research is needed to understand and confirm the effect of this drug in IBD. For the first time, we are evaluating the influence of EPO treatment in the TNBS-induced colitis model (without any other comorbidity). Furthermore, the used EPO doses were lower than those used in other studies, facilitating the translation of the obtained results to clinical practice. In IBD, the innate immune response is initiated immediately as soon as macrophages and dendritic cells of lamina propria [27, 28] . So, our findings suggest that EPO induces an anti-inflammatory effect in the early phase of the acute crisis in IBD, as it was able to decrease the cytokine concentration (TNF-a, IL-1b). These cytokines are produced during the characteristic innate immune response of the IBD (including CD and UC). The concentration of pro-inflammatory cytokines was significantly reduced in the colon tissues collected from TNBS-treated mice after EPO administration in a dose-dependent manner. This shows that EPO modulates the inflammatory process through the reduced expression of these pro-inflammatory cytokines, which is possibly attributed to blockage of NF-jB activation [10, 13] . The anti-inflammatory effect of EPO treatment is also confirmed by IL-10 measurements. EPO also promoted a significant increase in IL-10 levels in a dosedependent manner, constituting an important role in controlling inflammatory response in the TNBS-induced colitis. At a higher EPO dose, IL-10 concentration increased 4.8-fold comparing with colitic mice. As IL-10 itself functions as an antiinflammatory cytokine and limits excessive tissue disruption caused by inflammation [29, 30] , our findings suggest that the anti-inflammatory effect of EPO is due to both suppression of TNF-a and IL-1b and increased IL-10 production. These data are consistent with the mechanisms of action of EPO described in the literature [5, 9] .
The histopathological score was significantly reduced in the TNBS-treated mice receiving EPO treatment. EPO was able to decrease the severity and the extension of the colon injury, suggesting a remarkable recovery of the disease. These beneficial effects are coincident with other findings observed previously [10, 13, 14, 31] . Based on the histopathological assessment, we also conclude that EPO treatment significantly inhibits the acute inflammatory response. This effect was confirmed by the reduction in mucosal loss and inflammation, as well as the decrease in the percentage of intestine affected by the most severe lesion. The interaction of EPO with EPOR-bcR in the non-erythroid tissues is probably the mechanism of action responsible for pleiotropic effects of EPO [5] . This complex interaction promotes various mechanisms of action, such as inactivation of COX-2, STAT 3/5, PI3K-Akt, GSK-3b (and subsequent inactivation of NF-kB), as well as the direct inactivation of NF-kB [9] . The major influence of EPO in the inactivation of NF-kB seems to be crucial for its beneficial effects on the inflammatory response in IBD. Even, because some pharmacological approaches used in the clinical practice also act by inactivation of NF-kB, such as salicylates and corticosteroids [1] .
The inhibition of neutrophil infiltration in colonic tissue by EPO is also evident in the histopathological observations, confirming the reduced concentration of MPO in the inflamed colon after treatment. These findings suggest that beneficial effect of EPO treatment may be due in part to the suppression of inflammatory response via the inhibition of leucocyte infiltration [13, 31] .
Elevated levels of ALP were significantly attenuated by the EPO treatment by virtue of its anti-inflammatory potential (p < 0.001). These data are consistent with other previous findings, where anti-inflammatory drugs are able to decrease ALP level [32] . As intestinal ALP is expressed on the enterocytes and it is responsible for mucosal defence [33, 34] , EPO demonstrated a cytoprotective effect of intestinal mucosa after 4 days of daily treatment. In our study, we also registered an elevated ALP concentration in the EPO1000 group comparatively with other groups. This finding suggests a contribution of bone ALP, because EPO is able to increase mineral deposition in cultures of bone marrow stromal cells and thus enhance the expression of ALP activity [35] .
EPO treatment was able to attenuate diarrhoea and moderate the oedema of the anus in the colitic mice. Furthermore, EPO also significantly reduced the percentage of weight loss of mice during the experimental period at both administered doses. Curiously, the mice treated with the higher EPO dose presented a weight gain of around 7.3% of its initial weight. These data suggest similarities with other studies [10, 13] . EPO1000, ethanol and sham groups presented a considerable increase in body-weight with a gain of around 15% to 30% of its initial weight. In fact, they fasted for 24 hr from the day before the induction day. After induction, they woke up from anaesthesia, felt healthy and prepared to eat, unlike the other groups with experimental colitis, thus justifying the observed increase in body-weight. Variations in the length of any part of the colon are the developmental origin and may lead to a variety of acute and chronic pathological conditions [36] . A shortened colon characterizes TNBS-induced colitis, but EPO treatment attenuated the decrease in colon length induced by TNBS, suggesting a beneficial effect on recovery of IBD. Additionally, the determination of faecal haemoglobin can be useful in the detection of lesions accompanied by bleeding [37, 38] . However, the influence of EPO treatment in this biological marker has not been measured. We verified that EPO also has an influence on the intensity of haemorrhagic focus, as a significant reduction in faecal haemoglobin was observed after EPO treatment compared with the TNBS group (p < 0.0001) in a dose-dependent manner (p < 0.0001). Particularly, the higher EPO dose (1000 IU/kg) presented a faecal haemoglobin concentration similar to the EPO1000 group.
The well-documented extra-intestinal manifestations and complications of IBD, as well as the possible renal and hepatic side effects of pharmacotherapy, emphasize the need for periodic evaluation of renal and hepatic functions [39] [40] [41] . The evaluation of the influence of EPO in the extra-intestinal manifestations of IBD is truly relevant as it has never been investigated. We observed that a single daily dose of EPO is able to recover the renal and hepatic functions to normal levels, similar to the ethanol group. Our findings suggest that EPO has a beneficial effect on the extra-intestinal manifestations due to metabolic and physiological changes induced by IBD. Furthermore, we also can conclude that EPO does not promote renal and/or hepatic changes as adverse drug reaction in this experimental colitis model. More studies are needed to understand the mechanism besides the beneficial effect of EPO in the extra-intestinal manifestations of IBD. Probably, it is due to the interaction of EPO with EPO-bcR expressed on various non-erythroid tissues [11, 42] .
Additionally, it is known that EPO stimulates erythropoiesis, which leads to increased production of erythrocytes and, subsequently, an increase in haematocrit [43] . Moreover, some trials have raised safety concerns about the drug and suggested that pro-thrombotic effects may mitigate potential benefits. However, the small sample sizes produced underpowered results [44] . In fact, the influence of EPO treatment in the appearance of possible cardiovascular adverse events has never previously been evaluated in other studies about experimental colitis. Therefore, although our acute colitis model has been developed in only 4 days, the haematocrit level was measured at the end of the experimental period to evaluate the risk of related side effects. EPO-treated mice and the sham group registered normal haematocrit levels, according to reference levels in CD-1 mice between 43.9% and 53.3% [45] . These data suggest that EPO does not increase the risk of adverse events related to blood viscosity.
In conclusion, EPO had an anti-inflammatory effect in the development of experimental colitis within 4 days of treatment, without adverse events related to blood viscosity. The influence of EPO treatment in the TNBS-induced colitis is probably based on the inhibition of TNF-a and IL-1b formation (among other MPO effects that include attenuation of neutrophils infiltration) and stimulation of IL-10 production in the colon. Disclosure Statement.
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